AFJK

Aimei Health Technology Co., Ltd (AFJK) SWOT Analysis Analysis (2026)

Invetso Score: 1.7/10 — Weak · Last Updated: 2026-09-01

Monthly Update

No material changes this month.

Strengths

Score: 2.1 (Weak)

ROIC is negative at -5.8%, indicating AFJK is destroying invested capital versus profitable peers that compound returns above their cost of capital.

Cash conversion cycle is reported at zero, but with no supporting margin data this does not offset the weaker peer positioning implied by negative returns.

The absence of disclosed operating and gross margin metrics limits evidence of durable operating leverage, leaving AFJK structurally behind peers with clearer profitability profiles.

Weaknesses

Score:

Current and quick ratios of 0.01 signal extreme near-term liquidity weakness, leaving AFJK far below peers that typically maintain meaningful working-capital buffers.

Net debt to EBITDA is negative at -3.5, which suggests earnings are insufficient to support leverage comparisons and weakens balance-sheet credibility versus peers.

Debt-to-equity of 0.27 appears modest, but it is overshadowed by the liquidity shortfall, so capital structure remains fragile relative to stronger peers.

Opportunities

Score:

If AFJK can normalize liquidity, the gap to peers is large enough that even modest balance-sheet repair could materially improve relative positioning over 2–5 years.

The current absence of segment concentration data leaves room for a clearer business mix to emerge, which could help AFJK narrow the disclosure gap versus more transparent peers.

Any improvement in capital efficiency would have outsized peer-relative impact because the starting point is weak, making incremental operational gains more visible.

Threats

Score:

Persistent negative ROIC threatens long-term competitiveness because peers with positive capital returns can reinvest faster and widen structural gaps over time.

Severe liquidity weakness raises refinancing and execution risk, making AFJK more vulnerable than peers to working-capital shocks or tighter funding conditions.

Without margin disclosure or segment diversification evidence, AFJK faces a higher risk of underperformance versus peers that can defend margins and demand more effectively.

Overall Score

Score:

AFJK is structurally कमजोर versus peers, with negative capital returns and severe liquidity weakness outweighing any limited balance-sheet or disclosure-based upside.

Sources

  • Company filings (10-K, 10-Q, investor presentations)
  • Financial and market data providers
  • Public news and industry information

🔒 Go Beyond This Framework

This is one of 10 institutional-grade frameworks Invetso runs on Aimei Health Technology Co., Ltd. Unlock the complete analysis — SWOT, Economic Moat, Porter’s Five Forces, Management, PESTLE and the Invetso Quality Score.

Create your free account on Invetso →